Country | Only sponsor products transition (SABA excluded) | Whole market transition (SABA excluded) | Whole market transition (SABA included) |
UK | −47% | −84% | −89% |
Italy | −32% | −76% | −83% |
France | −14% | −70% | −89% |
Germany | −29% | −68% | −82% |
Spain | −15% | −79% | −86% |
Total five countries | −33% | −78% | −89% |
Sponsor products: this category includes sponsor products with the greatest patient use: beclometasone/formoterol/glycopyrronium bromide (‘Trimbow’), beclometasone/formoterol (‘Foster’ (or other brand names in different countries)) and beclometasone (‘Clenil’ (or other brand names in different countries)).
Whole market: this category includes all inhalers on the market.
GWP, global warming potential; SABA, short-acting β2-agonist .